Navigation Links
Why some prostate cancer returns
Date:5/27/2009

ORLANDO The majority of men who receive one of the standard treatments for localized prostate cancer surgery or radiation therapy have an excellent outcome.

But for the small group whose prostate cancer returns, a new study offers insight as to why treatment isn't effective.

The study a collaboration between researchers at the Josephine Ford Cancer Center at Henry Ford Hospital and Fox Chase Cancer Center shows that men with a low oxygen supply to their tumor have a higher chance of the prostate cancer returning, as found by increasing prostate-specific antigen (PSA) levels following treatment.

"After several years of research, we were able to show that low levels of oxygen to the tumor are highly related to a patient's outcome. Those with lower oxygen levels to the prostate cancer did not respond as well to radiation therapy, and the cancer returned more often," says Benjamin Movsas, M.D., senior study author and chair of the Department of Radiation Oncology at Henry Ford Hospital. Moreover, recent studies suggest the same finding also appears to apply to patients treated with surgery.

Results from the study will be presented May 31 at the American Society of Clinical Oncology (ASCO) annual meeting in Orlando.

Prostate cancer affects one in six men in the United States, but according to the American Cancer Society only one in 35 will die of it. The majority of all prostate cancer are diagnosed in men older than 65.

According to Dr. Movsas, oxygen being delivered to a tumor is critical to the treatment for many cancers. Radiation therapy, for example, creates free radicals that damage DNA in tumors, and oxygen acts as the mediator that perpetuates the free radicals.

That's why Dr. Movsas began his work nearly a decade ago to investigate low oxygen levels also known as tumor hypoxia in prostate cancer tumors while working at Fox Chase.

To measure the amount of oxygen being delivered to the tumors and surrounding areas, Dr. Movsas and his colleagues at Fox Chase used custom-made oxygen probes to test 57 patients with low or immediate risk of cancer prior to radiation therapy. The probe was used prior to "radioactive seeds" which were implanted in the prostate.

Dr. Movsas' initial research found that it is possible for prostate cancer tumors to have low oxygen levels. The next step was for the team to track the long-term correlation between low oxygen levels and PSA levels following treatment.

These new findings, being presented at ASCO, ultimately reveal that a tumor's oxygen supply can significantly predict a patient's outcome following treatment, independent from tumor stage or Gleason score, a classification of the grade of prostate cancer. Of the 57 patients, the study found that eight experienced an increase in their PSA levels about eight years following treatment.

"By identifying patients at risk with low oxygen levels in prostate tumors, we're now able to build on this research and begin to explore novel treatment options for this small subset of patients. It's possible we'll find that these patients will do best with a combination of radiation therapy and other novel approaches, such as angiogenesis therapy (targeting blood vessels) or possibly even gene therapy. That's where our research is taking us next," says Dr. Movsas. "Non-invasive methods to detect oxygen levels in tumors are also very important."


'/>"/>

Contact: Krista Hopson
khopson1@hfhs.org
313-874-7207
Henry Ford Health System
Source:Eurekalert

Related medicine news :

1. Enlarged Prostate and Erectile Dysfunction Are Subjects of Free Mens Health Seminar
2. Predicting higher risk for prostate cancer diagnosis
3. Carbohydrate restriction may slow prostate tumor growth
4. Advanced Prostate Cancer Deadlier in Younger Men
5. Younger men with advanced prostate cancer have shorter survival times
6. Medivation Announces Upcoming Presentation of New MDV3100 Data in Patients With Advanced Prostate Cancer at 45th American Society of Clinical Oncology Annual Meeting
7. Protein that suppresses androgen receptors could improve prostate cancer diagnosis, treatment
8. Research reveals molecular pathway behind invasive prostate cancers
9. An Aid to Tailoring Prostate Cancer Treatment
10. Long-term study shows low oxygen levels in prostate tumors can predict recurrence
11. Genetic marker may predict early onset of prostate cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from PsychTests.com reveals that behind the ...
(Date:6/24/2016)... ... ... June 19, 2016 is World Sickle Cell Observance Day. In an effort ... holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a pain ... Disease (SCD) is a disorder of the red blood cells, which can cause episodes ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
Breaking Medicine Technology: